Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection
Sara Lonardi, Halla Sayed Nimeiri, Chang Xu et al. · International Journal of Molecular Sciences · 2022
A majority of patients with metastatic colorectal cancer (mCRC) experience recurrence post curative-intent surgery. The addition of adjuvant chemotherapy has shown to provide limited survival benefits when applied to all patients. Therefore, a biomarker to assess molecular residual disease (MRD) accurately and guide treatment selection is highly desirable for high-risk patients. This feasibility study evaluated the prognostic value of a tissue comprehensive genomic profiling (CGP)-informed, personalized circulating tumor DNA (ctDNA) assay (FoundationOne®Tracker) (Foundation Medicine, Inc., Cambridge, MA, USA) by correlating MRD status with clinical outcomes. ctDNA analysis was performed retrospectively on plasma samples from 69 patients with resected mCRC obtained at the MRD and the follow-up time point. Tissue CGP identified potentially actionable alterations in 54% (37/69) of patients. MRD-positivity was significantly associated with lower disease-free survival (DFS) (HR: 4.97, 95% CI: 2.67−9.24, p < 0.0001) and overall survival (OS) (HR: 27.05, 95% CI: 3.60−203.46, p < 0.0001). Similarly, ctDNA positive status at the follow-up time point correlated with a marked reduction in DFS (HR: 8.78, 95% CI: 3.59−21.49, p < 0.0001) and OS (HR: 20.06, 95% CI: 2.51−160.25, p < 0.0001). The overall sensitivity and specificity at the follow-up time point were 69% and 100%, respectively. Our results indicate that MRD detection using the tissue CGP-informed ctDNA assay is prognostic of survival outcomes in patients with resected mCRC. The concurrent MRD detection and identification of actionable alterations has the potential to guide perioperative clinical decision-making.
Cited by 25 works. doi:10.3390/ijms231911529 Open-access PDF
Authors
- Sara Lonardi
- Halla Sayed Nimeiri
- Chang Xu
- Daniel R. Zollinger
- Russell William Madison
- Alexander D. Fine
- Ole V. Gjoerup
- Cosimo Rasola
- Valentina Angerilli
- Shruti Sharma
- Hsin-Ta Wu
- Charuta C. Palsuledesai
- Meenakshi Malhotra
- Alexey A. Aleshin
- Fotios Loupakis
- Elise T. Renkonen
- Priti S. Hegde
- Matteo Fassan
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Cancer Statistics, 2021
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- Comprehensive review of targeted therapy for colorectal cancer
- Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
- Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
- Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
- Carcinoembryonic Antigen Surge in Metastatic Colorectal Cancer Patients Responding to Oxaliplatin Combination Chemotherapy: Implications for Tumor Marker Monitoring and Guidelines